Integra LifeSciences Holdings Corporation Financial Statements (IART)
|
|
|
|
Report date
|
|
|
21.02.2020 |
23.02.2021 |
24.02.2022 |
22.02.2023 |
31.12.2023 |
|
04.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
1 518 |
1 372 |
1 542 |
1 558 |
1 542 |
|
1 565 |
|
Operating Income, bln rub |
|
|
179.0 |
151.4 |
197.2 |
238.9 |
111.5 |
|
86.9 |
|
EBITDA, bln rub |
? |
|
231.0 |
267.9 |
366.3 |
391.1 |
383.6 |
|
233.7 |
|
Net profit, bln rub |
? |
|
50.2 |
133.9 |
169.1 |
180.6 |
67.7 |
|
-6.54 |
|
|
OCF, bln rub |
? |
|
373.7 |
203.8 |
312.4 |
264.5 |
140.0 |
|
137.4 |
|
CAPEX, bln rub |
? |
|
134.5 |
63.9 |
48.1 |
47.1 |
66.9 |
|
99.4 |
|
FCF, bln rub |
? |
|
239.2 |
139.9 |
264.3 |
217.4 |
73.1 |
|
38.0 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
794.2 |
699.7 |
747.4 |
731.4 |
836.4 |
|
786.6 |
|
Cost of production, bln rub |
|
|
564.7 |
520.8 |
597.8 |
587.4 |
653.2 |
|
691.4 |
|
R&D, bln rub |
|
|
79.6 |
77.4 |
93.1 |
101.2 |
174.6 |
|
103.7 |
|
Interest expenses, bln rub |
|
|
54.0 |
71.6 |
50.4 |
49.6 |
51.4 |
|
70.5 |
|
|
Assets, bln rub |
|
|
3 303 |
3 615 |
3 782 |
3 890 |
3 782 |
|
4 066 |
|
Net Assets, bln rub |
? |
|
1 417 |
1 515 |
1 685 |
1 804 |
1 588 |
|
1 522 |
|
Debt, bln rub |
|
|
1 458 |
1 655 |
1 651 |
1 615 |
1 682 |
|
1 989 |
|
Cash, bln rub |
|
|
198.9 |
470.2 |
513.4 |
456.7 |
309.1 |
|
277.6 |
|
Net debt, bln rub |
|
|
1 259 |
1 185 |
1 138 |
1 159 |
1 373 |
|
1 712 |
|
|
Ordinary share price, rub |
|
|
58.3 |
64.9 |
67.0 |
56.1 |
43.6 |
|
37.8 |
|
Number of ordinary shares, mln |
|
|
85.6 |
84.7 |
84.7 |
83.0 |
78.2 |
|
76.4 |
|
|
Market cap, bln rub |
|
|
4 991 |
5 495 |
5 674 |
4 654 |
3 404 |
|
2 890 |
|
EV, bln rub |
? |
|
6 250 |
6 681 |
6 812 |
5 812 |
4 777 |
|
4 602 |
|
Book value, bln rub |
|
|
-569 |
-407 |
-474 |
-361 |
-535 |
|
-804 |
|
|
EPS, rub |
? |
|
0.59 |
1.58 |
2.00 |
2.18 |
0.87 |
|
-0.09 |
|
FCF/share, rub |
|
|
2.79 |
1.65 |
3.12 |
2.62 |
0.94 |
|
0.50 |
|
BV/share, rub |
|
|
-6.65 |
-4.81 |
-5.60 |
-4.35 |
-6.85 |
|
-10.5 |
|
|
EBITDA margin, % |
? |
|
15.2% |
19.5% |
23.7% |
25.1% |
24.9% |
|
14.9% |
|
Net margin, % |
? |
|
3.31% |
9.76% |
11.0% |
11.6% |
4.39% |
|
-0.42% |
|
FCF yield, % |
? |
|
4.79% |
2.55% |
4.66% |
4.67% |
2.15% |
|
1.32% |
|
ROE, % |
? |
|
3.54% |
8.84% |
10.0% |
10.0% |
4.27% |
|
-0.43% |
|
ROA, % |
? |
|
1.52% |
3.70% |
4.47% |
4.64% |
1.79% |
|
-0.16% |
|
|
P/E |
? |
|
99.4 |
41.0 |
33.6 |
25.8 |
50.3 |
|
-441.6 |
|
P/FCF |
|
|
20.9 |
39.3 |
21.5 |
21.4 |
46.6 |
|
76.0 |
|
P/S |
? |
|
3.29 |
4.01 |
3.68 |
2.99 |
2.21 |
|
1.85 |
|
P/BV |
? |
|
-8.77 |
-13.5 |
-12.0 |
-12.9 |
-6.36 |
|
-3.59 |
|
EV/EBITDA |
? |
|
27.1 |
24.9 |
18.6 |
14.9 |
12.5 |
|
19.7 |
|
Debt/EBITDA |
|
|
5.45 |
4.42 |
3.11 |
2.96 |
3.58 |
|
7.32 |
|
|
R&D/CAPEX, % |
|
|
59.1% |
121.1% |
193.5% |
214.9% |
261.1% |
|
104.4% |
|
|
CAPEX/Revenue, % |
|
|
8.87% |
4.66% |
3.12% |
3.02% |
4.34% |
|
6.35% |
|
| Integra LifeSciences Holdings Corporation shareholders |
